Cargando…
NLRP3 inflammasome as a novel therapeutic target for heart failure
Heart failure (HF) is a leading cause of mortality worldwide. The pathogenesis of HF is complex and has not yet been fully elucidated, which has slowed drug development and long-term treatments. Inflammasome-mediated responses occur during the progression of HF. It has been reported that energy meta...
Autores principales: | Wang, Shuangcui, Zhang, Jiaqi, Wang, Yuli, Jiang, Xijuan, Guo, Maojuan, Yang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Turkish Society of Cardiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878950/ https://www.ncbi.nlm.nih.gov/pubmed/35191381 http://dx.doi.org/10.5152/AnatolJCardiol.2021.580 |
Ejemplares similares
-
Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)
por: Zhang, Xiaolu, et al.
Publicado: (2023) -
Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
por: Wang, Shuangcui, et al.
Publicado: (2023) -
Interactions between NLRP3 inflammasome and glycolysis in macrophages: New insights into chronic inflammation pathogenesis
por: Yu, Qun, et al.
Publicado: (2021) -
The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
por: Fan, Jiwen, et al.
Publicado: (2022) -
NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
por: Zhang, Yun, et al.
Publicado: (2020)